Equities

Nuvalent Inc

NUVL:NSQ

Nuvalent Inc

Actions
  • Price (USD)75.19
  • Today's Change-1.45 / -1.89%
  • Shares traded385.66k
  • 1 Year change+188.75%
  • Beta--
Data delayed at least 15 minutes, as of Mar 28 2024 19:11 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer. It develops small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases and drive more durable responses. It is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-positive non-small cell lung cancer, and multiple discovery-stage research programs. Its product candidate, NVL-520, is being developed for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC). NVL-520 is a novel ROS1-selective inhibitor. Its product candidate, NVL-655, is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC. LC. NVL-655 is a brain-penetrant ALK-selective inhibitor. Its product candidate, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor.

  • Revenue in USD (TTM)0.00
  • Net income in USD-126.22m
  • Incorporated2017
  • Employees92.00
  • Location
    Nuvalent IncOne Broadway, 14th FloorCAMBRIDGE 02142United StatesUSA
  • Phone+1 (857) 357-7000
  • Fax+1 (302) 655-5049
  • Websitehttps://www.nuvalent.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Iovance Biotherapeutics Inc1.19m-444.04m3.94bn557.00--6.18--3,312.22-1.89-1.890.00512.280.0017----2,134.65-61.49-51.47-71.47-57.56-804.54---37,345.42-137,873.802.70--0.0017-------12.16--79.44--
Insmed Inc305.21m-749.57m4.06bn912.00------13.29-5.35-5.352.17-2.240.20440.85628.61334,657.90-50.20-40.96-58.32-46.8878.5277.99-245.59-212.923.75-17.211.39--24.3998.78-55.66---2.15--
10X Genomics Inc618.73m-255.10m4.40bn1.26k--5.93--7.11-2.18-2.185.286.220.62062.705.65491,443.20-25.59-25.52-29.39-29.0566.1575.88-41.23-48.534.11--0.00--19.8133.43-53.67--49.15--
Alkermes Plc1.66bn519.16m4.55bn2.10k9.023.787.662.743.022.079.797.200.81141.385.28792,097.6025.321.3433.691.7484.7983.3231.212.122.50--0.19470.0049.618.741,665.99---7.10--
Biohaven Ltd0.00-408.17m4.66bn239.00--10.81-----5.67-5.670.005.280.00----0.00-69.48---79.29--------------0.00------28.43------
Organon & Co6.26bn1.02bn4.72bn10.00k4.62--3.750.75313.993.9924.44-0.27380.54432.173.89626,300.008.8916.5311.6420.9759.8465.1216.3326.791.092.311.018.251.44-8.5211.56-13.8320.72--
Immunovant Inc0.00-243.45m4.72bn164.00--6.95-----1.83-1.830.004.680.00----0.00-41.70---44.49--------------0.00-------34.60------
Nuvalent Inc0.00-126.22m4.91bn92.00--7.01-----2.16-2.160.0010.940.00----0.00-20.78---21.70--------------0.00-------54.20------
Krystal Biotech Inc50.70m10.93m5.01bn229.002,002.496.43297.1898.890.08850.08851.8427.580.0737----221,393.001.59-11.501.66-12.0193.90--21.56-492.8517.55--0.00------107.81--39.49--
Halozyme Therapeutics, Inc.829.25m281.59m5.17bn373.0019.3161.6114.226.242.112.116.180.66110.4641.693.562,223,199.0015.7518.2216.9021.9776.8079.0533.9639.365.50139.090.94710.0025.6240.4339.31--26.82--
Revolution Medicines Inc11.58m-436.37m5.22bn378.00--2.86--451.12-3.77-3.770.102411.090.0081--3.9130,634.92-30.37-29.76-32.71-32.59-----3,768.28-606.93----0.00---67.27-10.50-75.46--38.82--
Madrigal Pharmaceuticals Inc0.00-373.63m5.34bn376.00--12.69-----19.93-19.930.0020.390.00----0.00-74.49-62.09-97.21-74.81------------0.2217-------26.50--132.01--
BridgeBio Pharma Inc9.30m-643.20m5.67bn550.00------609.38-3.95-3.950.0572-7.730.0159----16,914.54-111.72-72.44-148.01-89.7273.7194.41-7,021.94-1,225.66---13.344.49---88.02---33.67---40.94--
Blueprint Medicines Corp249.38m-506.98m5.80bn655.00--44.38--23.27-8.37-8.374.122.140.20790.33546.23380,732.80-42.26-29.92-50.67-34.0696.58---203.30-116.653.66-25.880.6465--22.2241.149.06--4.85--
Data as of Mar 28 2024. Currency figures normalised to Nuvalent Inc's reporting currency: US Dollar USD

Institutional shareholders

48.71%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 31 Dec 20238.72m15.25%
Paradigm BioCapital Advisors LPas of 31 Dec 20233.86m6.75%
The Vanguard Group, Inc.as of 31 Dec 20233.26m5.71%
Perceptive Advisors LLCas of 31 Dec 20232.92m5.10%
BlackRock Fund Advisorsas of 31 Dec 20232.04m3.57%
Fairmount Funds Management LLCas of 31 Dec 20231.92m3.37%
SSgA Funds Management, Inc.as of 31 Dec 20231.70m2.97%
Commodore Capital LPas of 31 Dec 20231.33m2.33%
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 20231.09m1.90%
Wellington Management Co. LLPas of 31 Dec 20231.01m1.77%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.